ABPI response to NICE fast track appraisal process

The National Institute for Health and Care Excellence is piloting a new cost-comparator appraisal process this summer for the review of selected low-risk appraisals.

This new approach to ensure some NICE decisions are made in a more efficient way is good news, especially for the patients that stand to benefit. It is important that NICE and its committees have sufficient capacity to issue timely guidance to the NHS, and this is one way to help, given the success of the pilot exercise. Victoria Barrett, Head of HTA & Market Access Policy at the ABPI

This is part of their work on recovery from the COVID-19 pandemic. NICE has been working hard to find new ways to publish guidance affected by the work programme pause in 2020, while also delivering the planned programme for 2021.

In response, Victoria Barrett, Head of HTA & Market Access Policy at the ABPI, said:

“This new approach to ensure some NICE decisions are made in a more efficient way is good news, especially for the patients that stand to benefit. It is important that NICE and its committees have sufficient capacity to issue timely guidance to the NHS, and this is one way to help, given the success of the pilot exercise.”

TAGS
  • NICE

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.